Clinical Trial RisksThere are risks to achieving the price target, including potential failed or inconclusive clinical trials and inability to secure adequate funding for drug development.
Financial HealthThe company ended the year with $14.8 million in cash, and has a loan with an annual interest rate of 14% maturing in 2026.
Statistical SignificanceThe primary endpoint of the Phase 2 Tailwind clinical trial did not reach statistical significance, likely due to small numbers of subjects.